TD Cowen Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $40
Benzinga Newsdesk 1 hour ago
Analyst RatingsNewsPrice Target
TD Cowen analyst Tyler Van Buren maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $35 to $40.
TD Cowen analyst Tyler Van Buren maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $35 to $40.